Novartis data demonstrates consistent efficacy and tolerability of Kisqali combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
- ?Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy extended PFS in all patients with and without visceral involvement compared to endocrine therapy alone; consistent with the overall study populations[3]?
- In patients with visceral metastasis, increased PFS benefit was seen regardless of burden of disease (=<?3 or > 3 lesions)[3]
- Approximately 41% of postmenopausal women with HR+ advanced breast cancer will develop their first metastasis in visceral organs, such as the lungs or liver, which is often associated with a poor prognosis[1],[2]